Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban-tamoxifen interaction study in women with breast cancer
NL-OMON23145Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of edoxaban and tamoxifen in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Edoxaban AUC over 24 hours, Edoxaban Cmax and 2 more. Started Sep 2019; status: recruiting.
02
Drugs
edoxabantamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON23145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23145.